Useful links
Unit of study_
PHAR7113: Cardiovascular and Renal
2024 unit information
This unit of study aims to develop an in-depth understanding of the physiology and pathophysiology of the cardiovascular and renal systems; aetiology, treatment, management and monitoring of patients with renal (including acute and chronic renal failure) and cardiovascular disease (including hypertension, heart failure, coronary heart disease, lipid disorders); It will also explore the role of the specialist cardiovascular/renal pharmacist in management and education of patients and other health care practitioners; public health approaches to the prevention of cardiovascular and renal disease; management and prevention of co-morbidities. Skills development will focus on application of this knowledge to the medication management of patient with cardiovascular and renal disease including interpretation of relevant clinical and laboratory tests, medication review and formulation of appropriate pharmacological and non-pharmacological care plans for these patients.
Unit details and rules
Managing faculty or University school:
Pharmacy
| Code | PHAR7113 |
|---|---|
| Academic unit | Pharmacy |
| Credit points | 6 |
|
Prerequisites:
?
|
None |
|---|---|
|
Corequisites:
?
|
None |
| Prohibitions:
?
|
None |
| Assumed knowledge:
?
|
None |
At the completion of this unit, you should be able to:
- LO1. discuss the prevalence of cardiovascular and renal disease in Australia, and why this varies amongst different population groups
- LO2. apply evidence-based guidelines to conduct structured risk assessments
- LO3. outline the benefits of a variety of preventative health strategies and public health approaches to improve cardiovascular health of the Australian population
- LO4. describe the anatomy of the cardiovascular and renal system; explain overall pathologenesis of cardiovascular and renal disease.
- LO5. define hypertension and resistant hypertension; discuss supporting evidence in the treatment of hypertension and resistant hypertension.
- LO6. define atherosclerosis in relation to heart disease; discuss supporting evidence in the treatment of heart disease, angina, dyslipidemia, myocardial infarction; discuss pharmacological and nonpharmacological treatment
- LO7. discuss the management of arrhythmias and atrial fibrillation; discuss supporting evidence in the treatment of arrhythmias and atrial fibrillation; discuss pharmacological and nonpharmacological treatment
- LO8. recognise the importance of stroke prevention in atrial fibrillation; assess stroke risk; discuss pharmacological treatments
- LO9. discuss management for heart failure; discuss supporting evidence in the treatment of heart failure; discuss pharmacological and nonpharmacological treatment
- LO10. discuss management of chronic renal failure; discuss supporting evidence in the treatment of chronic renal failure
Unit availability
This section lists the session, attendance modes and locations the unit is available in. There is a unit outline for each of the unit availabilities, which gives you information about the unit including assessment details and a schedule of weekly activities.
The outline is published 2 weeks before the first day of teaching. You can look at previous outlines for a guide to the details of a unit.
| Session | MoA ? | Location | Outline ? |
|---|---|---|---|
|
Semester 2 2024
|
Online | Camperdown/Darlington, Sydney |
Outline unavailable
|
Modes of attendance (MoA)
This refers to the Mode of attendance (MoA) for the unit as it appears when you’re selecting your units in Sydney Student. Find more information about modes of attendance on our website.
